Tohoku University Hospital - Dept of Otorhinolaryngology/Head and Neck Surgery
Welcome,         Profile    Billing    Logout  
 14 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BOISSELIER, Pierre
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
DURVALUNG, NCT05617963 / 2021-005920-39: Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax

Recruiting
2
550
Europe
Durvalumab
UNICANCER, AstraZeneca
Small Cell Lung Carcinoma
01/27
03/29
STEREOPOSTOP, NCT03401840: STEREO-POSTOP 01 (PostOperative Hypofractionated Stereotactic Body Radiotherapy ) - GORTEC 2017-03

Active, not recruiting
N/A
90
Europe
postoperative hypofractionated stereotactic radiotherapy
Centre Jean Perrin, GORTEC
Head and Neck Neoplasms
12/24
01/25
ETOILE, NCT02838602: Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors

Recruiting
N/A
250
Europe
Carbon ions therapy, Advanced external radiotherapy by Xrays or protons
Hospices Civils de Lyon
Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma
12/26
12/26
PRIMALung, NCT04790253: PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients ( Study)

Recruiting
N/A
600
Europe
Prophylactic cranial irradiation
European Organisation for Research and Treatment of Cancer - EORTC, UNICANCER
Limited Stage Small Cell Lung Cancer, Extensive-stage Small-cell Lung Cancer
04/28
04/28
Salas, Sebastien
NANORAY-312, NCT04892173 / 2021-002163-22: NBTXR3 With or Without Cetuximab in LA-HNSCC

Recruiting
3
500
Europe, Canada, Japan, US, RoW
NBTXR3, Functionalized hafnium oxide nanoparticles, Cetuximab, Erbitux, Radiation Therapy
Nanobiotix, Nanobiotix SA
Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged
06/26
06/27
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
PembroMetaRT, NCT04747054: Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Recruiting
3
102
Europe
Pembrolizumab, KEYTRUDA, Loco-regional radiotherapy, Chemotherapy
UNICANCER, GORTEC, National Cancer Institute, France
Squamous Cell Carcinoma of Head and Neck
10/25
10/29
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
MCLA-158-CL01, NCT03526835 / 2017-004745-24: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Recruiting
1/2
523
Europe, US
MCLA-158, petosemtamab, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
Merus N.V., Merus N.V.
Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
11/25
11/27
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1/2
374
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
SCHISM, NCT05083494: Real-time Monitoring of Concentration and Size Variations of Circulating Plasma Free DNA to Predict Early Response to Immunotherapies in Patients With Different Types of Cancer.

Recruiting
N/A
260
Europe
Assistance Publique Hopitaux De Marseille
Cancer
04/23
04/24
LENGLET, Alexis
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
STEREOLIVER, NCT03408665: Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer

Active, not recruiting
N/A
280
Europe
SBRT
Centre Oscar Lambret, Canceropôle Nord Ouest
Liver Cancer, Liver Metastases
12/26
12/27
KATORI, Yukio
NANORAY-312, NCT04892173 / 2021-002163-22: NBTXR3 With or Without Cetuximab in LA-HNSCC

Recruiting
3
500
Europe, Canada, Japan, US, RoW
NBTXR3, Functionalized hafnium oxide nanoparticles, Cetuximab, Erbitux, Radiation Therapy
Nanobiotix, Nanobiotix SA
Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged
06/26
06/27
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24

Download Options